2020 policy changes in Canada will create additional scrutiny on pharmaceutical pricing
Petra Ermacora | PRECISIONadvisors
October 21, 2019
The Canadian federal government has enacted the most significant changes to the Patented Medicines Regulations (PMR) since the establishment of the Patented Medicine Prices Review Board (PMPRB) more than three decades ago. The regulatory changes which are set to come into force in July 1, 2020 are generally consistent with the proposed reforms published in Canada Gazette, Part 1, December 2017.
We spoke with Olaf Koester, a former Canadian payer with national and provincial experience (Director of Manitoba Health), who is also a founding member of pan-Canadian Pharmaceutical Alliance which conducts joint provincial drug negotiations. Olaf is a member of the PRECISIONadvisors Payer Strategy Team, too.